Table 1 Baseline demographic of study cohort
Baseline Characteristics, N = 444* | N (%) |
|---|---|
Age, yrs, median (IQR) | 58 (21.0) |
Male Sex (%) | 267 (60) |
Body Mass Index*, kg/m2, median (IQR) | 26.8 (± 7.7) |
Place of Birth (%) | |
Australia/New Zealand | 179 (40) |
Pacific Island | 33 (7) |
Asia | 106 (24) |
North/South America | 16 (4) |
Middle East/Africa | 57 (13) |
Europe | 53 (12) |
Interpreter required (%) | 119 (27) |
Smoking status* (%) | |
Current | 13 (3) |
Former | 138 (31) |
Never | 277 (62) |
Co-morbidities % | |
Hypertension | 376 (85) |
Diabetes | 221 (50) |
Type 1 | 24 (5) |
Type 2 | 197 (45) |
Cardiac disease | 121 (27) |
Neurological disease | 106 (24) |
Respiratory disease | 89 (20) |
Haematological disease | 65 (15) |
Autoimmune disease | 45 (10) |
Liver disease | 35 (8) |
Current malignancy | 33 (7) |
Peripheral Vascular disease | 22 (5) |
Chronic Hepatitis B | 19 (4) |
Hepatitis C | 5 (1) |
eGFR at study start, ml/min/1.73m2, mean (SD) | 57 (21.9) |
Prior Dialysis and renal disease | |
Prior Dialysis Modality * (%) | |
Haemodialysis | 174 (39) |
Peritoneal Dialysis | 119 (27) |
Both | 107 (23) |
Pre-Emptive transplant | 38 (9) |
Modality change during study | 8 (2) |
Primary Cause of Renal disease (%) | |
Glomerulonephritis | 222 (50) |
Diabetes | 66 (15) |
ADPCKD | 47 (10) |
Obstructive Uropathy | 36 (8) |
Hypertension | 34 (8) |
Other | 39 (9) |
Transplant Information | |
Donor Type * (%) | |
Deceased | 308 (69) |
Live | 129 (29) |
Related | 88 (20) |
Unrelated | 41(9) |
Number of Transplants (%) | |
1 | 429 (96.6) |
2 | 14 (3.2) |
3 | 1 (0.2) |
Mismatches * (%) | |
0–1 | 28 (6) |
2–3 | 94 (21) |
4–6 | 221 (50) |
Transplant vintage, months, median (IQR) | 69.0 (± 111.0) |
MEDICATIONS | |
Baseline Immunosuppression (%) | |
Prednisolone | 411 (93) |
Prednisolone dose, mg, median (IQR) | 5.0 (5.0) |
Mycophenolate | 356 (80) |
Mycophenolate dose, mg, mean (SD) | 1193.5 (505.0) |
Tacrolimus | 321 (72) |
Tacrolimus level, ng/ml, median (IQR) | 6.3 (3.0) |
Ciclosporin | 43 (10) |
Ciclosporin level, ng/ml, median (IQR) | 134 (219) |
Everolimus | 42 (10) |
Everolimus level, ng/ml, mean (SD) | 5.3 (1.8) |
Sirolimus | 22 (5) |
Sirolimus level, ng/ml, mean (SD) | 5.8 (1.6) |
Azathioprine | 39 (9) |
Azathioprine, mg, mean (SD) | 83 (37.0) |
ATG | 46 (10) |
Time from ATG, yrs, median (IQR) | 3.0 (6.3) |
Use of Any Blood thinner | 135 (30) |
COVID-19 VACCINATION DOSES* | |
0 | 17 (4) |
1 | 4 (1) |
2 | 75 (17) |
3 | 239 (54) |
4 | 105 (24) |